

A61K

(21) Int. Application Number: PCT/JP89/01323	(51) International Patent Classification ⁵ : A61K 9/20	(11) Int. Publication Number: WO 90/07327
(22) Int. Filing Date: 28 December 1989 (28.12.89)	A1	(43) Int. Publication Date: 12 July 1990 (12.07.90)
<p>(30) Priority data: 63/331821 28 December 1988 JP (28.12.88)</p>		
<p>(71) Applicant (for all designated States except US): TAISHO PHARMACEUTICAL CO., LTD. [JP/JP]; 24-1, Takata 3-chome, Toshima-ku, Tokyo 171 (JP).</p>		
<p>(72) Inventors; and:</p>		
<p>(75) Inventors/Applicants (for US only): YUASA, Hiroshi [JP/JP]; Higashigaoka Apartment Room 305, 12-1, Hatagaya 2-chome, Shibuya-ku, Tokyo 151 (JP). KANAYA, Yoshio [JP/JP]; 15-3, Nogata 5-chome, Nakano-ku, Tokyo 165 (JP). OMATA, Kazuki [JP/JP]; 22-6, Honchou 6-chome, Meguro-ku, Tokyo 152 (JP).</p>		
<p>(74) Agent: KITAGAWA, Tomizou; Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo 171 (JP).</p>		
<p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.</p>		
<p>Published With international search report.</p>		
<p>(54) Title: STRESS SCATTERING METHOD IN TABLETING</p>		
<p>(57) Abstract:</p>		
<p>This invention relates to a tableting composition containing minute gelatine balls and/or foams as stress scattering agents so as to minimize the disintegration of microcapsules on the transformation of medicine during tableting; and a stress scattering method in tableting. The use of the tableting composition according to the present invention enables tablets to be made without causing microencapsulated medicine powder, enzymes, germs or substances of a low melting point to be transformed or disintegrated.</p>		

(21) Int. Application Number: PCT/US89/05798	(51) International Patent Classification ⁵ : A61K 9/70, A61L 15/00	(11) Int. Publication Number: WO 90/07328
(22) Int. Filing Date: 22 December 1989 (22.12.89)	A1	(43) Int. Publication Date: 12 July 1990 (12.07.90)
<p>(30) Priority data: P 38 44 247.7 29 December 1988 DE (29.12.88)</p>		
<p>(71) Applicant (for all designated States except US): RIKER LABORATORIES, INC. [US/US]; P.O. Box 33427, Saint Paul, MN 55133 (US).</p>		
<p>(72) Inventors; and:</p>		
<p>(75) Inventors/Applicants (for US only): KRECKEL, Karl, W. [DE/DE]; Wilbecke 12-14, P.O. Box 1340, D-4280 Borken I (DE). ZERBE, Horst-Georg [DE/DE]; Wilhelm-Busch-Strasse 4, D-4281 Velen (DE).</p>		
<p>(74) Agents: SPRAGUE, Robert, W. et al.; Minnesota Mining and Manufacturing Company, P.O. Box 33427, St. Paul, MN 55133-3427 (US).</p>		
<p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p>		
<p>Published With international search report.</p>		
<p>(54) Title: APPLICATION SYSTEM FOR DRUG CONTAINING MICROEMULSIONS</p>		
<p>(57) Abstract</p>		
<p>The invention deals with devices, in particular with bandage strips, for a transdermal delivery of drugs to patients, whereby the drug formulations include highly viscous preparations, topical solutions of a low viscosity and micro-emulsions of a low viscosity containing the drugs. Depending on the consistency of the medium containing the drug, the drug formulation is stored in a reservoir, consisting, e.g., of a punched out cavity or of an absorbent piece of material, which is encased or supported by a carrier element (a formed material piece or a non-woven fleece tape) adhering to the skin by means of a skin-compatible adhesive, whereby specially formed protective films are applied at the filling and delivery side during the storage of the device to prevent a lateral migration, and whereby during its use, the device can be refilled with dosed amounts by the patient without requiring a removal of the device from the skin surface to be treated (Fig. 2).</p>		